Abou-Alfa, G. K., Ren, Z., Erinjeri, J. P., Heo, J., Lencioni, R., Arai, Y., Bouattour, M., Gonzalez-Carmona, M. A., Guo, Y., Xu, A., Alves, G. V., Dechaphunkul, A., Ho, G. F., Lim, Y. N., Hu, H., Tekumalla, S. H., Dave, V., Monzonis, X., Kudo, M., Fan, J. (2026). Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba4000